A single-center, open-label, phase II, safety and efficacy study of Panzem nanocrystal colloidal dispersion [2-methoxyestradiol] administered orally in combination with protracted oral fixed-dose temozolomide to patients with recurrent glioblastoma multiforme

Trial Profile

A single-center, open-label, phase II, safety and efficacy study of Panzem nanocrystal colloidal dispersion [2-methoxyestradiol] administered orally in combination with protracted oral fixed-dose temozolomide to patients with recurrent glioblastoma multiforme

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Oct 2014

At a glance

  • Drugs 2-methoxyestradiol; Temozolomide
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Sponsors CASI Pharmaceuticals; EntreMed
  • Most Recent Events

    • 24 Nov 2008 Status changed from active, no longer recruiting to completed, reported by ClinicalTrials.gov. The actual completion date was October 2008.
    • 09 Jul 2008 Actual initiation date added form Clinicaltrials.gov.
    • 09 Jul 2008 Actual patient number (15) added from ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top